Axsome Therapeutics, Inc. (AXSM) Discusses Approval of AUVELITY for Agitation Associated With Dementia Due to Alzheimer's Disease - Slideshow
Axsome Therapeutics has announced the approval of its drug AUVELITY for the treatment of agitation associated with dementia due to Alzheimer's disease. The company presented details on the approval through a slide deck released on May 1, 2026. This marks a significant development in addressing behavioral symptoms in Alzheimer's patients.
- ▪Axsome Therapeutics received approval for AUVELITY to treat agitation in dementia due to Alzheimer's disease.
- ▪The approval was announced via a slide deck published by the company on May 1, 2026.
- ▪AUVELITY is now positioned as a new therapeutic option for a challenging symptom in Alzheimer's disease management.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4897614-axsome-therapeutics-inc-axsm-discusses-approval-of-auvelity-for-agitation-associated-with"},"author":{"@type":"Person","name":"SA Transcripts","url":"https://seekingalpha.com/author/sa-transcripts"},"publisher":{"@context":"http://schema.org","@type":"Organization","address":{"@type":"PostalAddress","streetAddress":"244 5th Ave","addressLocality":"New York","addressRegion":"NY","postalCode":"10001","addressCountry":"US"},"alternateName":["SeekingAlpha","SA"],"brand":[{"@type":"Brand","name":"Seeking Alpha Premium","url":"https://seekingalpha.com/subscriptions/premium"},{"@type":"Brand","name":"Seeking Alpha…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
